Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from NurExone Biologic ( (TSE:NRX) ) is now available.
NurExone Biologic plans to highlight its exosome-based regenerative medicine platform at two major March 2026 industry events, NANO.IL.2026 in Jerusalem and the Advanced Therapies Congress in London, where CEO Dr. Lior Shaltiel will speak on nano-scale biology, industrial biotech approaches and the translation of advanced therapies into scalable, regulated products. The company views these conferences as complementary venues to showcase its technology for minimally invasive central nervous system therapies to scientific, industrial and investor audiences, potentially strengthening its profile in the nano-biotech and advanced therapies ecosystems.
Alongside the conference plans, NurExone reported a management change, with Jacob Licht set to step down as CEO of U.S. subsidiary Exo-Top Inc. and Vice President, Corporate Development at the end of March 2026, after which his responsibilities will be absorbed by the existing management team. The update underscores NurExone’s intention to maintain operational continuity while continuing to advance ExoPTEN toward clinical milestones and to position its exosome platform as a commercial solution for partners seeking targeted delivery technologies.
More about NurExone Biologic
NurExone Biologic Inc. is a Toronto- and Haifa-based biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries. Listed on the TSX Venture Exchange, OTCQB and Frankfurt, its lead candidate ExoPTEN has shown promising preclinical results for acute spinal cord and optic nerve injuries, and the company also aims to supply quality exosomes and minimally invasive delivery systems to other drug developers, supported by its U.S. subsidiary Exo-Top Inc.
Average Trading Volume: 20,124
Technical Sentiment Signal: Hold
Current Market Cap: C$46.87M
For an in-depth examination of NRX stock, go to TipRanks’ Overview page.